Right. If the CVR payout on just the approval with the OS label alone is around $7.40, I can't see any reason why he would take anything less than this. The $7.40 doesn't even take into consideration any of the future royalties due; and, it's pretty clear to me that this will be the new SOC - further, melanoma and other cancers will put this well over a $1 billion drug (of which CVRs payout above $1B)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.